SCHEMBL2064664

SCHEMBL2064664

Cc1ccc(-c2cn3cc(-c4ccc(CO)c(F)c4)ccc3n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A3 P47895 7/20 0.61
SLC2A1 P11166 1/20 0.56
NPC1 O15118 6/20 0.55
ALDH1A1 P00352 6/20 0.55
RAB9A P51151 5/20 0.55
SMN1; SMN2 Q16637 5/20 0.55
KDM4E B2RXH2 3/20 0.55
PAX8 Q06710 2/20 0.55
KMT2A Q03164 2/20 0.55
MEN1 O00255 1/20 0.55
MITF O75030 1/20 0.55
KDM5A P29375 1/20 0.55
KDM5C P41229 1/20 0.55
LMNA P02545 2/20 0.51
MAPT P10636 1/20 0.51
NR4A2 P43354 4/20 0.51
CYP2C9 P11712 1/20 0.51
KCNH2 Q12809 1/20 0.51
APP P05067 2/20 0.50
TP53 P04637 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2063842 0.90 ALDH1A3 (0.61) ALDH1A3SLC2A1NPC1ALDH1A1RAB9A
SCHEMBL2063563 0.82 ALDH1A3 (0.69) ALDH1A3NPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL2063105 0.80 NR4A2 (0.67) ALDH1A3NPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL1472658 0.79 NR4A2 (0.80) ALDH1A3SLC2A1NPC1ALDH1A1RAB9A
SCHEMBL2064019 0.78 NR4A2 (0.81) ALDH1A3SLC2A1NPC1ALDH1A1RAB9A
SCHEMBL13325772 0.78 ALDH1A3 (0.87) ALDH1A3SLC2A1NPC1ALDH1A1RAB9A
SCHEMBL2065293 0.77 NR4A2 (0.65) ALDH1A3SLC2A1NPC1ALDH1A1RAB9A
SCHEMBL2064088 0.76 NR4A2 (0.61) ALDH1A3SLC2A1NPC1ALDH1A1RAB9A
SCHEMBL13359717 0.76 NPC1 (0.68) ALDH1A3SLC2A1NPC1ALDH1A1RAB9A
SCHEMBL1472508 0.75 NR4A2 (0.67) ALDH1A3SLC2A1NPC1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2262803-B1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2012-10-17 EP claimed
US-8148370-B2 Polysubstituted derivatives of 2-aryl-6-phenyl-imidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2012-04-03 US claimed
US-20110065699-A1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US claimed
EP-2262803-B1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2012-10-17 EP disclosed
US-8148370-B2 Polysubstituted derivatives of 2-aryl-6-phenyl-imidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2012-04-03 US disclosed
US-20110065699-A1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065699-A1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF ABL1, JAK2, REN ALDH1A3 1255/4885SLC2A1 1173/4885NPC1 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.